These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 33856242)

  • 1. COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.
    Achiron A; Dolev M; Menascu S; Zohar DN; Dreyer-Alster S; Miron S; Shirbint E; Magalashvili D; Flechter S; Givon U; Guber D; Stern Y; Polliack M; Falb R; Gurevich M
    Mult Scler; 2021 May; 27(6):864-870. PubMed ID: 33856242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose.
    Dreyer-Alster S; Menascu S; Mandel M; Shirbint E; Magalashvili D; Dolev M; Flechter S; Givon U; Guber D; Stern Y; Miron S; Polliack M; Falb R; Sonis P; Gurevich M; Achiron A
    J Neurol Sci; 2022 Mar; 434():120155. PubMed ID: 35091386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Sinopharm vaccine for people with Multiple Sclerosis: Study of adverse reactions and disease activity.
    Kavosh A; Ashtari F; Naghavi S; Adibi I; Shaygannejad V; Karimi Z; Arabi S; Rahimi M; Mazaheri S
    Mult Scler Relat Disord; 2022 May; 61():103708. PubMed ID: 35349883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Relapse After COVID-19 Vaccination Among Patients With Multiple Sclerosis in France: A Self-Controlled Case Series.
    Moisset X; Leray E; Chenaf C; Taithe F; Vukusic S; Mulliez A; Clavelou P
    Neurology; 2024 Sep; 103(5):e209662. PubMed ID: 39141880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection.
    Stastna D; Menkyova I; Drahota J; Hrnciarova T; Kubala Havrdova E; Vachova M; Andelova M; Kleinova P; Kovarova I; Krasulova E; Preiningerova JL; Novakova I; Novotna K; Novotna M; Nytrova P; Pavlickova J; Srpova B; Storey K; Ticha V; Tyblova M; Uher T; Vodehnalova K; Horakova D
    Mult Scler Relat Disord; 2022 Sep; 65():104014. PubMed ID: 35803085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis.
    Stefanou MI; Palaiodimou L; Theodorou A; Christodoulou MV; Tzartos JS; Tzanetakos D; Kitsos D; Chondrogianni M; Zouvelou V; Dardiotis E; Tzavellas E; Syrigou E; Benetou V; Paraskevas GP; Tsiodras S; Tsivgoulis G; Giannopoulos S
    Mult Scler; 2023 Apr; 29(4-5):585-594. PubMed ID: 36722184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple sclerosis relapse after COVID-19 vaccination: A case report-based systematic review.
    Nabizadeh F; Ramezannezhad E; Kazemzadeh K; Khalili E; Ghaffary EM; Mirmosayyeb O
    J Clin Neurosci; 2022 Oct; 104():118-125. PubMed ID: 36029752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea.
    Lee YW; Lim SY; Lee JH; Lim JS; Kim M; Kwon S; Joo J; Kwak SH; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH; Bae S
    J Korean Med Sci; 2021 May; 36(21):e153. PubMed ID: 34060261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea.
    Bae S; Lee YW; Lim SY; Lee JH; Lim JS; Lee S; Park S; Kim SK; Lim YJ; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH
    J Korean Med Sci; 2021 May; 36(17):e115. PubMed ID: 33942579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 vaccination and relapse activity: A nationwide cohort study of patients with multiple sclerosis in Denmark.
    Stastna D; Elberling F; Pontieri L; Framke E; Horakova D; Drahota J; Nytrova P; Magyari M
    Eur J Neurol; 2024 Mar; 31(3):e16163. PubMed ID: 38015454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran.
    Paybast S; Hejazi SA; Molavi P; Habibi MA; Naser Moghadasi A
    Mult Scler Relat Disord; 2022 Apr; 60():103712. PubMed ID: 35247752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience.
    Kim SH; Wi YM; Yun SY; Ryu JS; Shin JM; Lee EH; Seo KH; Lee SH; Peck KR
    J Korean Med Sci; 2021 Apr; 36(14):e107. PubMed ID: 33847085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Immunological and Clinical Perspective on Vaccinations in Multiple Sclerosis Patients: Are They Safe after All?
    Witman Tsur S; Adrian Zaher E; Tsur M; Kania K; Kalinowska-Łyszczarz A
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel.
    Lotan I; Wilf-Yarkoni A; Friedman Y; Stiebel-Kalish H; Steiner I; Hellmann MA
    Eur J Neurol; 2021 Nov; 28(11):3742-3748. PubMed ID: 34288285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient.
    Etemadifar M; Sigari AA; Sedaghat N; Salari M; Nouri H
    Hum Vaccin Immunother; 2021 Oct; 17(10):3481-3483. PubMed ID: 34015240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In subjects 16 years of age and older, is messenger RNA vaccine BNT162b2 against COVID-19 effective and safe?].
    Lanthier L; Carignan A; Plourde MÉ; Cauchon M
    Rev Med Interne; 2021 Mar; 42(3):227-228. PubMed ID: 33612319
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of COVID-19 vaccination on multiple sclerosis activity as reflected by MRI.
    Ganelin-Cohen E; Buxbaum C; Bosak N; Sobol S; Vaknin-Dembinsky A; Hellmann MA; Wilf-Yarkoni A; Regev K; Pustovoyt E; Shifrin A; Wexler Y; Rozenberg A
    Brain Behav; 2024 Jul; 14(7):e3587. PubMed ID: 38940313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BNT162b2 vaccine uptake and effectiveness in UK healthcare workers - a single centre cohort study.
    Azamgarhi T; Hodgkinson M; Shah A; Skinner JA; Hauptmannova I; Briggs TWR; Warren S
    Nat Commun; 2021 Jun; 12(1):3698. PubMed ID: 34140469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System.
    Jeon M; Kim J; Oh CE; Lee JY
    J Korean Med Sci; 2021 May; 36(17):e114. PubMed ID: 33942578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.